NCT00102219已完成2 期
A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 77
- 试验地点
- 12
- 主要终点
- To assess the antitumor activity of pemetrexed plus doxorubicin, as measured by overall tumor response rate
研究概览
简要总结
This is a non-randomized Phase 2 study testing pemetrexed and doxorubicin in combination for locally advanced or metastatic breast cancer. Both pemetrexed and doxorubicin have been combined with other drugs, but they have not yet been combined with each other. It is expected that the patient will benefit from the different mechanisms of action of the two drugs. However, there is no guarantee that the patient will benefit from this treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of locally advanced or metastatic breast cancer that is not amenable to local treatment.
- •Patients must be chemo-naive or have received only neoadjuvant and/or adjuvant chemotherapy.
- •At least one measurable lesion.
- •No chemotherapy within 4 weeks prior to enrollment.
- •Signed informed consent from the patient.
排除标准
- •Prior chemotherapy for metastatic breast cancer.
- •Prior treatment with any anthracyclines or anthracenedione-containing regimen.
- •Treatment within the last 30 days with any drug that has not received regulatory approval.
- •Pregnancy and/or breast feeding.
- •Inability or unwillingness to take folic acid or vitamin B12 supplementation.
结局指标
主要结局
To assess the antitumor activity of pemetrexed plus doxorubicin, as measured by overall tumor response rate
次要结局
- Time to progressive disease
- Progression-free survival
- Overall survival
研究者
研究点 (12)
Loading locations...
相似试验
进行中（未招募）
1 期
A phase 2 study of ALIMTA plus doxorubicin administered every 21 days in patients with advanced breast cancerAdvanced breast cancerEUCTR2004-000691-13-ESilly S.A.70
已完成
1 期
Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast CancerBreast CancerNCT00097383Eli Lilly and Company
Unknown
2 期
Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast TumorBreast CancerNCT01176799National University Hospital, Singapore73
进行中（未招募）
1 期
Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer - PANTHERArecurrent/advanced follicular, papillary or anaplastic thyroid cancerMedDRA version: 14.1Level: LLTClassification code 10016935Term: Follicular thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10002240Term: Anaplastic thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-001032-12-DEniversitätsklinikum Schleswig-Holstein47
招募中
不适用
A randomized phase II study of doxorubicin combined with thalidomide versus doxorubicin alone for patients with unresectable hepatocellular carcinoma.hepatocellular cancerNL-OMON21497ot applicable30